)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Biovica International
Biovica International (BIOVIC) investor relations material
Biovica International Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary9 Sep, 2026
Executive summary
Achieved 56% year-over-year net sales growth in Q1, primarily driven by strong Pharma Services momentum.
Implemented organizational restructuring and cost-saving measures, including leadership changes and a refocused US commercial strategy.
Strengthened leadership with a new CEO and CFO, and proposed a renewed Board with commercial and life sciences expertise.
Positioned for the next phase of growth with a fully guaranteed SEK 29.2 million rights issue.
Financial highlights
Net sales reached KSEK 4,043, up from KSEK 2,596, a 56% increase year-over-year (57% in local currency).
Operating loss (EBIT) was KSEK -20,334, compared to KSEK -19,334, including KSEK 2,200 in restructuring costs.
Cash flow from operating activities improved to KSEK -16,100 from KSEK -17,196.
Cash and cash equivalents at quarter-end were KSEK 51,588, up from KSEK 16,305.
Earnings per share after dilution was SEK -0.07, compared to SEK -0.18 year-over-year.
Outlook and guidance
Updated strategic and financial plan to be communicated in the coming months.
Confident in having sufficient financial resources for at least twelve months, subject to rights issue completion.
Focus remains on sustainable, profitable growth through scientific innovation and commercial execution.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biovica International
- Strong sales growth and improved financials set the stage for US-focused expansion.BIOVIC
Q4 25/26 - Q3 net sales up 46% year-over-year, with strong U.S. momentum and improved cash position.BIOVICQ3 25/26
- Q2 sales up 16% YoY, SEK 122.3m raised, and cash flow positivity targeted for 2027.BIOVICQ2 25/26
- US IVD sales up 72% year-over-year, SEK 122M raised, and growth momentum continues.BIOVICQ1 25/26
- US sales up 120% in Q4, major partnerships, and SEK 80M rights issue to fund expansion.BIOVICQ4 24/25
- Major U.S. contracts and clinical data drive growth, but sales and funding risks persist.BIOVICQ2 24/25
- US sales up 48–50%, cash flow improved, but next year's funding depends on warrants.BIOVICQ1 24/25
- Q4 sales soared 225% YoY, with US momentum, cost cuts, and funding supporting 2025 targets.BIOVICQ4 23/24
- Sales doubled and partnerships expanded, but liquidity risk persists despite improved cash flow.BIOVICQ3 24/25
Next Biovica International earnings date
BioStock Life Science Summit 20265 Nov, 2026
Biovica International
Next Biovica International earnings date
BioStock Life Science Summit 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Biovica International AB, a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome. The company's focus is on prediction of treatment efficacy and prognosis, thereby providing physicians with objective decision-making tools that enable informed treatment choice. The company is based in Uppsala, Sweden.